Foghorn Therapeutics Inc.

NASDAQ:FHTX

Biotechnology

Healthcare
$1.79 +2.35%

+$0.10 today

Market cap
$107.33M
Beta
2.89
P/E (TTM)
-3.8
EPS (TTM)
-$1.08
52W Low $3.27High $6.95

Volume 0.53M

Average 0.15M

FHTX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Foghorn Therapeutics Inc.NASDAQ: FHTX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $18.26M fell 15.6% year over year, behind the -9.4% change in trailing-twelve-month research & development. Sequentially, it fell 20.4% from the prior quarter. Over 3 fiscal years it compounded at -6.8% a year.

Context

  • Research & development amounted to 276.5% of revenue in FY2025, down 141.7 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -15.6% toward the trailing-twelve-month pace of -9.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$18.26M-20.4% QoQ
Last fiscal yearDec 2025
$85.47M-9.6% YoY
LTMMar 2026
$82.1M-9.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.6%——
1 year-9.6%——
3-year CAGR-6.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
85.47M USD
Year-over-year change
-9.6%
4-year CAGR
+1.6%

Research & Development vs competitors

How FHTX compares with its peers on the latest reported figures

  • FHTX's LTM Mar 2026 research & development of $82.1M is the 6th highest of the 11 companies compared; the peer median is $83.78M.
  • Its year-over-year change of -9.4% is the 7th highest of 11, against a peer median of +10.7%.
  • Research & development amounts to 290.9% of revenue for FHTX, versus a peer median of 216.6%.
FHTX Competitors Peer median
Research & Development for FHTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMRXImmuneering CorporationLTM Mar 2026$10.68B +22061.7%+5.1%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$143.25M +11.2%+28.8%2496.5%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$101.99M +14.6%+8.4%46.8%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$98.25M -44.3%-8.8%216.6%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$91.32M -20.8%-13.4%131.9%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$82.1M -9.4%-6.8%290.9%
PYXSPyxis Oncology, Inc.LTM Mar 2026$76.25M +21.5%-5.1%550.2%
HUMAHumacyte, Inc.LTM Mar 2026$73.35M -11.4%+3.1%3638.2%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$64.86M +10.1%-2.5%91.2%
ZURAZura Bio LimitedLTM Mar 2026$46.35M +48.2%+21.1%—
SGMTSagimet Biosciences Inc.LTM Mar 2026$30.71M -36.7%+16.2%—
Peer median (excluding FHTX) $83.78M+10.7%+4.1%216.6%

Competitors are the stored peer set for FHTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.32M19.23M34.16M22.6M30.91M
Cost of Revenue00003.33M
Gross Profit1.32M19.23M34.16M22.6M27.58M
Gross Margin100.0%100.0%100.0%100.0%89.2%
Research & Development80.33M105.62M109.69M94.53M85.47M
Selling, General & Admin21.73M30.75M32.37M28.36M27.55M
Operating Expenses102.05M136.37M142.06M125.29M109.68M
Depreciation & Amortization3.23M3.32M3.45M3.12M3.33M
EBITDA(96.19M)(105.56M)(90.75M)(97.17M)(70.95M)
EBITDA Margin-7292.4%-549.0%-265.7%-429.9%-229.5%
Operating Income(100.73M)(117.14M)(107.91M)(102.68M)(82.11M)
Operating Margin-7637.1%-609.2%-315.9%-454.3%-265.6%
Interest Income59K5.68M10.88M11.9M8.75M
Interest Expense1.91M0000
Other Income / Expenses(586K)8.26M13.71M16.06M7.82M
Income Before Tax(101.32M)(108.88M)(94.2M)(86.62M)(74.28M)
Pre-Tax Margin-7681.6%-566.3%-275.8%-383.2%-240.3%
Income Tax Expense004.23M00
Net Income(101.32M)(108.88M)(98.43M)(86.62M)(74.28M)
Net Margin-7681.6%-566.3%-288.2%-383.2%-240.3%
EPS (Basic)(2.78)(2.62)(2.34)(1.58)(1.18)
EPS (Diluted)(2.78)(2.62)(2.34)(1.58)(1.18)
Weighted Avg Shares37.17M41.59M41.97M54.9M62.98M
Weighted Avg Shares (Diluted)37.17M41.59M41.97M54.9M62.98M

Foghorn Therapeutics Inc.

NASDAQ:FHTX

Intrinsic Alpha fair value

Locked

Current Price

$1.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.